Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Why?

Strongest counted support: The passage directly reports 86.8% sensitivity and the 3.2% and 15.6% false-positive rates for the testing cohort. weight 1.800000 evidence

Suppressed as dependent: The primary paper reports 86.8% sensitivity for stage I–II PDAC and false-positive rates of 3.2% and 15.6% in the stated control groups.; Cancer Network independently reports the same testing-cohort performance figures for the PANXEON composite.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of...” · 1 claim · 29 September 2026
• “In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of...” · 1 claim · 28 September 2026
• “In an international prospective biomarker study, the PANXEON blood assay combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8%...” · 1 claim · 28 September 2026

Evidence for

• Nature Medicine reports 86.8% sensitivity for stage I–II PDAC with 3.2% and 15.6% false-positive rates in low- and high-risk controls.

  From Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

• Cancer Network independently reports the same testing-cohort performance figures for the PANXEON composite.

  From PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer Read 2026-09-28 Relevance DIRECT Steps 0 Counted

• City of Hope reports roughly 87% stage I–II detection with 3% and 16% false-positive rates in low- and high-risk groups.

  From New Study: Blood Test Shows Promise for Detecting Pancreatic Cancer at Its Earliest Stages Read 2026-09-28 Relevance STRONG Steps 0 Counted

  Institutional summary independently rounds the study’s 86.8%, 3.2%, and 15.6% testing-cohort figures.

• The passage directly reports 86.8% sensitivity and the 3.2% and 15.6% false-positive rates for the testing cohort.

  From Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

• The primary paper reports 86.8% sensitivity for stage I–II PDAC and false-positive rates of 3.2% and 15.6% in the stated control groups.

  From Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Primary Nature Medicine evidence directly confirms the existing quantitative claim.

Evidence against

None.

Qualifications

• The source explicitly labels the figures as testing-cohort results and separates low-risk from high-risk controls.

  From Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The sampling and control-group scope materially limits generalization beyond the reported cohort.

Suppressed as dependent

Evidence	Group	Kept instead
da938f94		50cdf67f
23b0ee43	95aaa2eb	dfe17fbf

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

From	Relationship	To
68c78451	NARROWS	ff28a421

Review checklist

Review checks: 1 of 4

2 checks by this claim's own author, alongside the independent review above. 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	c98eb782, 4bcfc24a, 50cdf67f, dfe17fbf

Summary

Contribution history

seq	event	detail
14178	APPENDED
14179	ACCEPT	AUTOMATIC_AFTER_VALIDATION
14186	LINK_EVIDENCE	by 1efd24fe (accepted)
14188	LINK_EVIDENCE	by 1efd24fe (accepted)
14203	LINK_EVIDENCE	by 1efd24fe (accepted)
14205	TASK_RESULT	by 1efd24fe (accepted)
14215	TASK_RESULT	by 1efd24fe (accepted)
20778	LINK_EVIDENCE	by 1efd24fe (accepted)